Identification of disease- and therapy-associated proteome changes in the sera of patients with myelodysplastic syndromes and del(5q)

Leukemia

Volumn 24, Issue 11, 2010, Pages 1875-1884

  Chen, C ^a   Bowen, D T ^b   Giagounidis, A A N ^c   Schlegelberger, B ^d   Haase, S ^c   Wright, E G ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b St James's Institute of Oncology   (United Kingdom)

^c ST JOHANNES HOSPITAL   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

mass spectrometry; myelodysplastic syndromes; ProteinChip array analysis; SELDI TOF MS; serum proteome; treatment

Indexed keywords

LENALIDOMIDE; PROTEOME;

5Q- SYNDROME; ADULT; AGED; ARTICLE; CHROMOSOME ARM; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HUMAN; IONIZATION; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; PROTEOMICS; TIME OF FLIGHT MASS SPECTROMETRY;

EID: 78149468991     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2010.182     Document Type: Article

References (40)

1. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med 1999; 340: 1649-1660.
2. Hofmann WK, Ottmann OG, Ganser F, Hoelzer D. Myelodysplastic syndromes: clinical features. Semin Hematol 1996; 33: 177-185.
3. Schiffer CA. Clinical issue in the management of patients with myelodysplasia. Hematology 2006; 1: 205-210.
4. Hofmann WK, Koeffler HP. Myelodysplastic syndrome. Annu Rev Med 2005; 56: 1-16.
5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982; 51: 189-199.
6. Cazzola M, Malcovati L. Myelodysplastic syndromes-coping with ineffective hematopoiesis. N Engl J Med 2005; 352: 536-538.
7. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res 2003; 27: 95-120.
8. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol 2000; 72: 131-133.
9. Petricoin EF, Liotta LA. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr Opin Biotechnol 2004; 15: 24-30.
10. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002; 292: 587-592.
11. Xiao Z, Luke BT, Izmirlian G, Umar A, Lynch PM, Phillips RK et al. Serum proteomic profiles suggest celecoxib-modulated targets and response predictors. Cancer Res 2004; 64: 2904-2909.
12. Miyamae T, Malehorn DE, Lemster B, Mori M, Imagawa T, Yokota S et al. Serum protein profile in systemic-onset juvenile idiopathic arthritis differentiates response versus nonresponse to therapy. Arthritis Res Ther 2005; 7: R746-R755.
13. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E et al. Myelodysplastic Syndrome-003 Study Investigators. Lenali-domide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006; 355: 1456-1465.
14. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. World Health Organization (WHO) international working group. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671-3674.
15. Agranoff D, Fernandez-Reyes D, Papadopoulos MC, Rojas SA, Herbster M, Loosemore A et al. Identification of diagnostic markers for tuberculosis by proteomic fingerprinting of serum. Lancet 2006; 368: 1012-1021.
16. McMorran BJ, Patat SA, Carlin JB, Grimwood K, Jones A, Armstrong DS et al. Novel neutrophil-derived proteins in bronchoalveolar lavage fluid indicate an exaggerated inflammatory response in pediatric cystic fibrosis patients. Clin Chem 2007; 53: 1782-1791.
17. Noble JL, Dua RS, Coulton GR, Isacke CM, Gui GP. A comparative proteinomic analysis of nipple aspiration fluid from healthy women and women with breast cancer. Eur J Cancer 2007; 43: 2315-2320.
18. Villar-Garea A, Griese M, Imhof AJ. Biomarker discovery from body fluids using mass spectrometry. Chromatogr B Analyt Technol Biomed Life Sci 2007; 849: 105-114.
19. Diamandis EP. Mass spectrometry as a diagnostic and a cancer biomarker discovery tool: opportunities and potential limitations. Mol Cell Proteomics 2004; 3: 367-378.
20. Poon TC. Opportunities and limitations of SELDI-TOF-MS in biomedical research: practical advices. Expert Rev Proteomics 2007; 4: 51-65.
21. Pusztai L, Gregory BW, Baggerly KA, Peng B, Koomen J, Kuerer HM et al. Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoad-juvant or adjuvant chemotherapy for breast carcinoma. Cancer 2004; 100: 1814-1822.
22. Zhang Z, Bast Jr RC, Yu Y, Li J, Sokoll LJ, Rai AJ et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004; 64: 5882-5890.
23. Fung ET, Yip TT, Lomas L, Wang Z, Yip C, Meng XY et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays. Int J Cancer 2005; 115: 783-789.
24. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB et al. Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 2006; 116: 271-284.
25. Piñeiro M, Alava MA, González-Ramón N, Osada J, Lasierra P, Larrad L et al. ITIH4 serum concentration increases during acute-phase processes in human patients and is up-regulated by interleukin-6 in hepatocarcinoma HepG2 cells. Biochem Biophys Res Commun 1999; 263: 224-229.
26. Piñeiro M, Andrés M, Iturralde M, Carmona S, Hirvonen J, Pyörälä S et al. ITIH4 (inter-alpha-trypsin inhibitor heavy chain 4) is a new acute-phase protein isolated from cattle during experimental infection. Infect Immun 2004; 72: 3777-3782.
27. González-Ramón N, Hoebe K, Alava MA, Van Leengoed L, Piñeiro M, Carmona S et al. Pig MAP/ITIH4 and haptoglobin are interleukin-6-dependent acute-phase plasmaproteins in porcine primary cultured hepatocytes. Eur J Biochem 2000; 267: 1878-1885.
28. Mundle SD, Reza S, Ali A, Mativi Y, Shetty V, Venugopal P et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999; 140: 201-207.
29. Rai AJ, Zhang Z, Rosenzweig J, Shih IeM, Pham T, Fung ET et al. Proteomic approaches to tumor marker discovery. Arch. Pathol Lab Med 2002; 126: 1518-1526.
30. Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ et al. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006; 94: 1898-1905.
31. Escher N, Kaatz M, Melle C, Hipler C, Ziemer M, Driesch D et al. Posttranslational modifications of transthyretin are serum markers in patients with mycosis fungoides. Neoplasia 2007; 9: 254-259.
32. Liu L, Liu J, Dai S, Wang X, Wu S, Wang J et al. Reduced transthyretin expression in sera of lung cancer. Cancer Sci 2007; 98: 1617-1624. (Pubitemid 47308460)
33. Miguet L, Bogumil R, Decloquement P, Herbrecht R, Potier N, Mauvieux L et al. Discovery and identification of potential bio-markers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. J Proteome Res 2006; 5: 2258-2269.
34. Koomen JM, Shih LN, Coombes KR, Li D, Xiao LC, Fidler IJ et al. Plasma protein profiling for diagnosis of pancreatic cancer reveals the presence of host response proteins. Clin Cancer Res 2005; 11: 1110-1118.
35. Kozak KR, Amneus MW, Pusey SM, Su F, Luong MN, Luong SA et al. Identification of biomarkers for ovarian cancer using strong anion-exchange ProteinChips: potential use in diagnosis and prognosis. Proc Natl Acad Sci USA 2003; 100: 12343-12348.
36. Woong-Shick A, Sung-Pil P, Su-Mi B, Joon-Mo L, Sung-Eun N, Gye-Hyun N et al. Identification of hemoglobin-alpha and -beta subunits as potential serum biomarkers for the diagnosis and prognosis of ovarian cancer. Cancer Sci 2005; 96: 197-201.
37. Aivado M, Spentzos D, Germing U, Alterovitz G, Meng XY, Grall F et al. Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci USA 2007; 104: 1307-1312.
38. Cho WC, Yip TT, Ngan RK, Yip TT, Podust VN, Yip C et al. ProteinChip array profiling for identification of disease- and chemotherapy-associated biomarkers of nasopharyngeal carcinoma. Clin Chem 2007; 53: 241-250.
39. Vermeulen R, Lan Q, Zhang L, Gunn L, McCarthy D, Woodbury RL et al. Decreased levels of CXC-chemokines in serum of benzene-exposed workers identified by array-based proteomics. Proc Natl Acad Sci USA 2005; 102: 17041-17046.
40. Pellagatti A, Jädersten M, Forsblom AM, Cattan H, Christensson B, Emanuelsson EK et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci USA 2007; 104: 11406-11411.